Asia
Dezhan Healthcare Subsidiary Achieves Positive Results in Phase 3 Trial for HPV-16/18 Jab
Dezhan Healthcare (SHE:000813) subsidiary Beijing Orient Biopharmaceutical Technology achieved positive top-line results in its phase 3 trial for the vaccine for HPV-16/18-related diseases, according to a Thursday disclosure to the Shenzhen bourse.The vaccine showed a "superior" response rate and showed overall safety for Chinese trial subjects.The VGX-3100 jab reduces or helps avoid fertility-related risks in treating lesions in the cervix, the filing said.
SHE:000813
